THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 91 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2014. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $121 | -14.8% | 14,069 | +2.5% | 0.00% | 0.0% |
| Q2 2023 | $142 | -16.0% | 13,723 | -11.8% | 0.00% | 0.0% |
| Q1 2023 | $169 | -99.8% | 15,565 | +35.1% | 0.00% | 0.0% |
| Q1 2022 | $110,000 | -4.3% | 11,525 | +10.6% | 0.00% | 0.0% |
| Q4 2021 | $115,000 | -50.6% | 10,423 | +8.6% | 0.00% | -50.0% |
| Q1 2018 | $233,000 | -44.0% | 9,599 | -35.7% | 0.00% | -33.3% |
| Q4 2017 | $416,000 | +274.8% | 14,931 | +205.5% | 0.00% | +200.0% |
| Q2 2016 | $111,000 | +68.2% | 4,887 | +40.2% | 0.00% | – |
| Q1 2016 | $66,000 | +73.7% | 3,486 | +51.3% | 0.00% | – |
| Q4 2015 | $38,000 | +11.8% | 2,304 | -25.9% | 0.00% | – |
| Q3 2015 | $34,000 | +183.3% | 3,108 | +229.2% | 0.00% | – |
| Q2 2015 | $12,000 | -7.7% | 944 | +28.8% | 0.00% | – |
| Q1 2015 | $13,000 | +18.2% | 733 | +0.5% | 0.00% | – |
| Q4 2014 | $11,000 | -45.0% | 729 | -16.0% | 0.00% | – |
| Q3 2014 | $20,000 | -28.6% | 868 | 0.0% | 0.00% | – |
| Q2 2014 | $28,000 | – | 868 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chescapmanager LLC | 1,134,718 | $23,160,000 | 2.47% |
| Baupost Group | 8,735,168 | $178,285,000 | 1.42% |
| Orbimed Advisors | 6,219,110 | $126,932,000 | 1.19% |
| CM Management, LLC | 50,000 | $1,021,000 | 0.76% |
| Tekla Capital Management LLC | 456,296 | $9,313,000 | 0.32% |
| Rock Springs Capital Management LP | 682,600 | $13,932,000 | 0.30% |
| Virtus ETF Advisers LLC | 32,871 | $671,000 | 0.28% |
| Cormorant Asset Management, LP | 550,000 | $11,226,000 | 0.25% |
| DAFNA Capital Management LLC | 41,165 | $840,000 | 0.20% |
| PEREGRINE CAPITAL MANAGEMENT LLC | 484,206 | $9,883,000 | 0.18% |